Biogen Idec Inc (BIIB) 286.75 $BIIB
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
New TYSABRI(R) Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
Business Wire - Thu May 01, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI(R) (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFNB) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014).
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Now Funded in Saskatchewan
CNW Group - Thu May 01, 5:00AM CDT
Biogen Idec Canada announces today that Saskatchewan is the first province in Canada to fund TECFIDERATM (dimethyl fumarate) as an Exception Drug Status (EDS) benefit through the Saskatchewan MS Drugs Program. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1 )
Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference
Business Wire - Wed Apr 30, 3:02PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 39th Annual Healthcare Conference. The webcast will be live on Wednesday, May 7, 2014 at 10:40 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Critical Alerts For Weibo, ExOne, Biogen Idec, Verizon Communications, and Delta Air Lines Released By InvestorsObserver
PR Newswire - Wed Apr 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WB, XONE, BIIB, VZ, and DAL.
New Data Reinforce Efficacy of TECFIDERA(R) (Dimethyl Fumarate) in MS Patients with High Disease Activity
Business Wire - Wed Apr 30, 6:31AM CDT
New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis (RRMS), as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia.
ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the strategic alliance between Isis and Biogen Idec (NASDAQ:BIIB) has been honored with the Alliance 2014 Breakthrough Award. The award, sponsored by Thomson Reuters Recap, was presented at the Allicense 2014 Conference in San Francisco on April 29, 2014.
Biogen Idec to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - Wed Apr 30, 2:36AM CDT
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management Conference in Philadelphia, PA on October 14-15, 2014. The two day conference will feature interactive discussions on innovative solutions to resource planning issues.
Biogen Idec to Present New Two-Year Data from the PLEGRIDY(TM) (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Business Wire - Tue Apr 29, 6:30AM CDT
--- Additional Analyses of Year-One ADVANCE Results Show High Rates of Freedom from Measured Disease Activity and Recovery from Relapses -
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Hemophilia B Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrpb8k/hemophilia_b) has announced the addition of the "Global Hemophilia B Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Emergent BioSolutions Inc. - Sangamo BioSciences, Inc. - Novo Nordisk A/S - rEVO Biologics - Pfizer Inc. - OPKO Health, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Catalyst Biosciences, Inc. - Amarna Therapeutics B.V. - Asklepios BioPharmaceutical, Inc. - LFB Biotechnologies, S.A.S - UniQure NV - AlphaMab Co., Ltd Drug Profiles - coagulation factor IX-Fc (recombinant) - coagulation factor IX (recombinant) - GNR-001 - trenonacog alfa - coagulation factor IX-Fc (recombinant) - trenonacog alfa - CSL-654 - NN-7999 - LR-769 - BAX-817 - nonacog alfa biosimilar - AMT-060 - AskBio-009 - Gene Therapy For Hemophilia B - CSL-689 - PF-05280602 - concizumab - Gene Therapy To Activate Factor IX For Hemophilia B - MOD-9017 - MOD-5017 - ALN-AT3 - eptacog alfa biosimilar - Factor IX - ZFP Nucleases for Hemophilia - IB1-007 - Long Acting Blood Coagulation Factor IX - Long Acting Coagulation Factor VIIa - CB-2679d - MOD-5014 - Gene Therapy For Hemophilia B - AZ-10047130 - AZ-10776241 - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/mr...mophilia_b
Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint
Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
New TYSABRI(R) Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
Business Wire - Thu May 01, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI(R) (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFNB) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014).
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Now Funded in Saskatchewan
CNW Group - Thu May 01, 5:00AM CDT
Biogen Idec Canada announces today that Saskatchewan is the first province in Canada to fund TECFIDERATM (dimethyl fumarate) as an Exception Drug Status (EDS) benefit through the Saskatchewan MS Drugs Program. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1 )
Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference
Business Wire - Wed Apr 30, 3:02PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 39th Annual Healthcare Conference. The webcast will be live on Wednesday, May 7, 2014 at 10:40 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Critical Alerts For Weibo, ExOne, Biogen Idec, Verizon Communications, and Delta Air Lines Released By InvestorsObserver
PR Newswire - Wed Apr 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WB, XONE, BIIB, VZ, and DAL.
New Data Reinforce Efficacy of TECFIDERA(R) (Dimethyl Fumarate) in MS Patients with High Disease Activity
Business Wire - Wed Apr 30, 6:31AM CDT
New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis (RRMS), as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia.
ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
PR Newswire - Wed Apr 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the strategic alliance between Isis and Biogen Idec (NASDAQ:BIIB) has been honored with the Alliance 2014 Breakthrough Award. The award, sponsored by Thomson Reuters Recap, was presented at the Allicense 2014 Conference in San Francisco on April 29, 2014.
Biogen Idec to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - Wed Apr 30, 2:36AM CDT
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management Conference in Philadelphia, PA on October 14-15, 2014. The two day conference will feature interactive discussions on innovative solutions to resource planning issues.
Biogen Idec to Present New Two-Year Data from the PLEGRIDY(TM) (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Business Wire - Tue Apr 29, 6:30AM CDT
--- Additional Analyses of Year-One ADVANCE Results Show High Rates of Freedom from Measured Disease Activity and Recovery from Relapses -
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Hemophilia B Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrpb8k/hemophilia_b) has announced the addition of the "Global Hemophilia B Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Emergent BioSolutions Inc. - Sangamo BioSciences, Inc. - Novo Nordisk A/S - rEVO Biologics - Pfizer Inc. - OPKO Health, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Catalyst Biosciences, Inc. - Amarna Therapeutics B.V. - Asklepios BioPharmaceutical, Inc. - LFB Biotechnologies, S.A.S - UniQure NV - AlphaMab Co., Ltd Drug Profiles - coagulation factor IX-Fc (recombinant) - coagulation factor IX (recombinant) - GNR-001 - trenonacog alfa - coagulation factor IX-Fc (recombinant) - trenonacog alfa - CSL-654 - NN-7999 - LR-769 - BAX-817 - nonacog alfa biosimilar - AMT-060 - AskBio-009 - Gene Therapy For Hemophilia B - CSL-689 - PF-05280602 - concizumab - Gene Therapy To Activate Factor IX For Hemophilia B - MOD-9017 - MOD-5017 - ALN-AT3 - eptacog alfa biosimilar - Factor IX - ZFP Nucleases for Hemophilia - IB1-007 - Long Acting Blood Coagulation Factor IX - Long Acting Coagulation Factor VIIa - CB-2679d - MOD-5014 - Gene Therapy For Hemophilia B - AZ-10047130 - AZ-10776241 - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/mr...mophilia_b
Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint
Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).
